Drug intelligence / Profile preview

Meramirt

Development stage
Preclinical
Lead developer
Fidia Farmaceutici
Administration
Ophthalmic
01

Overview

Meramirt is a sterile ophthalmic solution and class IIa medical device formulated as eye drops containing hypromellose (hydroxypropyl methylcellulose 0.3%) and inositol (0.1) for the hydration and lubrication of the ocular surface in patients with ocular disorders such as dry eye disease related to environmental, visual, and mechanical stress, including asthenopia and accommodative effort.[1][2][6] Hypromellose acts as a tear substitute by thickening and stabilizing the tear film on the corneal surface, forming a transparent, viscoelastic, protective layer that improves ocular lubrication and comfort, while inositol serves primarily as an antioxidant osmolyte that may counteract free-radical–mediated oxidative stress and support metabolic processes in ocular muscles involved in accommodation.[1][2][6] The product is marketed as a non-pharmacological medical device rather than a systemic pharmaceutical, is instilled topically as 1–2 drops in the conjunctival sac several times daily, and can be used by contact lens wearers to alleviate symptoms of dry eye and visual fatigue.[1][2][4]

Brand names
Meramirt

Beyond the preview

Go deeper on Meramirt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meramirt.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call